OPRX · Optimizerx Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $109.43M | $92.13M | $71.52M | $62.45M | $61.29M | $43.31M |
| Cost of Revenue | $35.83M | $32.75M | $28.62M | $23.48M | $25.65M | $19.21M |
| Gross Profit | $73.59M | $59.38M | $42.90M | $38.97M | $35.64M | $24.11M |
| R&D | $0 | - | - | - | - | $0 |
| SG&A | - | - | - | $27.70M | - | - |
| Total Operating Expenses | $61.90M | $73.08M | $69.30M | $51.26M | $35.28M | $26.24M |
| D&A | $4.33M | $4.33M | $2.40M | $1.97M | $2.09M | $2.08M |
| Operating Income | $11.69M | ($13.71M) | ($26.40M) | ($12.29M) | $361.1K | ($2.14M) |
| Interest Expense | $5.29M | $6.16M | $1.45M | - | - | - |
| Income Tax | $1.82M | $725.0K | ($7.60M) | - | - | - |
| Net Income | $5.13M | ($20.11M) | ($17.57M) | ($11.44M) | $378.1K | ($2.21M) |
| EPS - Basic | $0.28 | ($1.10) | ($1.03) | ($0.64) | $0.02 | ($0.15) |
| EPS - Diluted | $0.27 | ($1.10) | ($1.03) | ($0.64) | $0.02 | ($0.15) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $23.36M | $13.38M | $13.85M | $18.21M | $84.68M | $10.52M |
| Accounts Receivable | $37.75M | $38.21M | $36.25M | $22.16M | $24.80M | $17.89M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $1.64M | $2.16M | $2.23M | $1.55M | $606.8K | $618.3K |
| Current Assets | $64.72M | $53.97M | $54.33M | $98.58M | $115.11M | $32.86M |
| Total Assets | $176.92M | $171.17M | $183.37M | $134.65M | $140.99M | $60.33M |
| Current Liabilities | $21.26M | $18.65M | $17.88M | $8.40M | $9.37M | $10.03M |
| Long-term Debt | $21.42M | $30.82M | $34.23M | - | - | - |
| Total Liabilities | $48.62M | $54.17M | $56.82M | $8.54M | $9.61M | $10.35M |
| Stockholders' Equity | $128.29M | $117.00M | $126.55M | $126.11M | $131.38M | $49.97M |
| Retained Earnings | ($79.24M) | ($84.37M) | ($64.26M) | ($46.69M) | ($35.25M) | ($35.63M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $18.71M | $4.89M | ($7.24M) | $10.65M | $726.0K | ($6.31M) |
| Investing Cash Flow | $68.0K | ($450.0K) | ($25.34M) | ($58.18M) | ($486.0K) | ($124.7K) |
| Financing Cash Flow | ($8.80M) | ($4.91M) | $28.22M | ($18.95M) | $73.92M | ($1.90M) |
| CapEx | $58.0K | $112.0K | $87.1K | $81.0K | $100.3K | $68.0K |
| Free Cash Flow | $18.66M | $4.78M | ($7.33M) | $10.57M | $625.7K | ($6.38M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 67.3% | 64.5% | 60.0% | 62.4% | 58.1% | 55.7% |
| Operating margin | 10.7% | -14.9% | -36.9% | -19.7% | 0.6% | -4.9% |
| EBITDA margin | 14.6% | -10.2% | -33.6% | -16.5% | 4.0% | -0.1% |
| Net margin | 4.7% | -21.8% | -24.6% | -18.3% | 0.6% | -5.1% |
| Free cash flow margin | 17.0% | 5.2% | -10.2% | 16.9% | 1.0% | -14.7% |
| FCF / Net income | 3.64 | -0.24 | 0.42 | -0.92 | 1.65 | 2.89 |
| R&D / Revenue | 0.0% | - | - | - | - | 0.0% |
| SG&A / Revenue | - | - | - | 44.4% | - | - |
| Effective tax rate | 26.2% | - | - | - | - | - |
| Return on assets | 2.9% | -11.7% | -9.6% | -8.5% | 0.3% | -3.7% |
| Return on equity | 4.0% | -17.2% | -13.9% | -9.1% | 0.3% | -4.4% |
| Return on invested capital | 5.8% | -7.3% | -13.0% | - | - | - |
| Liquidity | ||||||
| Current ratio | 3.04 | 2.89 | 3.04 | 11.74 | 12.29 | 3.28 |
| Quick ratio | 3.04 | 2.89 | 3.04 | 11.74 | 12.29 | 3.28 |
| Cash ratio | 1.10 | 0.72 | 0.77 | 2.17 | 9.04 | 1.05 |
| Leverage | ||||||
| Debt / Equity | 0.17 | 0.26 | 0.27 | - | - | - |
| Debt / Assets | 0.12 | 0.18 | 0.19 | - | - | - |
| Debt / EBITDA | 1.34 | - | - | - | - | - |
| Interest coverage | 2.2x | -2.2x | -18.2x | - | - | - |
| Equity multiplier | 1.38 | 1.46 | 1.45 | 1.07 | 1.07 | 1.21 |
| Liabilities / Assets | 0.27 | 0.32 | 0.31 | 0.06 | 0.07 | 0.17 |
| Efficiency | ||||||
| Asset turnover | 0.62 | 0.54 | 0.39 | 0.46 | 0.43 | 0.72 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 126d | 151d | 185d | 129d | 148d | 151d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | 17d | 24d | 28d | 24d | 9d | 12d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | 45.4x | - | - | - | 3105.5x | - |
| P / B | 1.8x | 0.8x | 1.9x | 2.4x | 8.4x | 9.2x |
| P / S | 2.1x | 1.0x | 3.4x | 4.8x | 17.9x | 10.7x |
| EV / EBITDA | 14.4x | - | - | - | 414.3x | - |
| Growth | ||||||
| Revenue growth (YoY) | 18.8% | 28.8% | 14.5% | 1.9% | 41.5% | 76.1% |
| Revenue CAGR (3y) | 20.6% | 14.5% | 18.2% | 36.4% | 42.4% | 52.9% |
| Revenue CAGR (5y) | 20.4% | 30.2% | 27.5% | 38.8% | 51.2% | 43.1% |
| Gross profit growth (YoY) | 23.9% | 38.4% | 10.1% | 9.3% | 47.8% | 56.1% |
| Operating income growth (YoY) | - | 48.1% | -114.8% | - | - | 42.2% |
| Net income growth (YoY) | - | -14.5% | -53.6% | - | - | 29.8% |
| EPS growth (YoY) | - | -6.8% | -60.9% | - | - | 34.8% |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 290.6% | - | - | 1589.8% | - | -264.8% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 9.7% | -7.6% | 0.4% | -4.0% | 162.9% | 11.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$109.43M totalLife Science Companies$109.21M · 99.8%
Other Revenue$215.0K · 0.2%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.73
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
8/9
Strong
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-Business Services, NEC
Comparing OptimizeRx Corp against the 5 most active filers in the same SIC group.